Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Is Ventricle Size a Good Measure of AD?
19 July 2008. Using data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), Robert Bartha and colleagues at the Robarts Research Institute in London, Ontario, Canada, have evaluated the possibility that the rate of ventricular enlargement over six months could be a useful marker for Alzheimer disease progression. By comparing change in ventricle size with changes in two common psychometric tests, they found that absolute changes in ventricle size provided a more sensitive measure of disease progression than cognitive changes. Their results, published online in Brain on July 11, suggest that rates of ventricular enlargement, determined by serial MRI, could serve as a feasible short-term marker in multicenter clinical trials for AD. A second study on brain size, this one from Jeffrey Burns and colleagues at the University of Kansas in Kansas City, offers a possible modifier of brain tissue loss by showing that fitness level correlates with brain size in patients with early AD.

Researchers in the ADNI study, a multicenter, longitudinal imaging and biomarker discovery program, have accumulated thousands of MRI measures from hundreds of people with AD, mild cognitive impairment (MCI), and normal elderly controls. In the current study, first author Sean Nestor and colleagues applied an automated method of determining ventricular volume to ADNI MRI data from 504 subjects who had both baseline and six-month follow-up scans. Nestor and coworkers found that at baseline, absolute ventricular volume was highest in AD patients, and that in the MCI group it was also significantly elevated over controls. All of the groups showed further enlargement over six months, with the rate being greatest in the patients with AD, and also significantly elevated in the MCI group compared to normal controls. Among AD patients, the test was sensitive to ApoE allele status, where people with ApoE4 showed significantly more ventricular enlargement than those without.

In the MCI group, the change in ventricular volume tracked with cognitive changes and disease progression as measured by the Mini-Mental State Exam (MMSE), the ADAS-cog battery, and conversion to AD. For people with MCI, an increase in ventricular volume correlated with decline in MMSE score and increase in ADAS-cog. People with MCI who progressed to AD during the six-month follow-up showed twice the rate of ventricle enlargement than people with stable MCI.

Among anatomical measures, loss of hippocampal volume has been shown to predict the progression of AD (see ARF related news story). Ventricular enlargement is the flip side of brain shrinkage, and the authors speculate that their measure is so sensitive, in part, because it captures the loss of hippocampal volume. However, measuring ventricle volume has some advantages over determining hippocampal size, the authors write. The calculation of ventricular volume is easily automated because ventricle boundaries show up as a sharp line of contrast between tissue and cerebrospinal fluid in MRI. This automation may contribute to the high reproducibility of the measure even in a multicenter design.

The results suggest that changes in ventricular volume measured over time could provide a more sensitive read of the clinical progression of AD than the currently accepted endpoints of cognitive testing. By the authors’ calculations, the ability to measure significant (20 percent) changes in ventricle size in a clinical trial would require hundreds of subjects, versus thousands for the MMSE or ADAS-cog endpoints. “As a potential measure of disease progression for multicenter studies of both AD and MCI subjects, ventricular enlargement measures would significantly reduce the number of subjects required to demonstrate a change from the natural history of Alzheimer’s disease progression,” the authors conclude.

One finding of the Nestor study is that there are large variations in the rate of ventricular enlargement within the AD or MCI groups. That suggests a range of responses to AD pathology among individuals, which could be affected by environmental factors. The Burns study, which appeared in the July 15 issue of Neurology, asks whether fitness level affects brain changes seen early in AD. The researchers measured the fitness of 57 early-stage AD patients, and a similar number of non-demented subjects, during exercise on a treadmill, and determined whole brain volume by MRI. Their results indicate that subjects with AD had a modestly but significantly reduced maximum oxygen consumption (a measure of cardiorespiratory fitness) compared to non-demented subjects. Fitness level correlated with brain volume in the AD group, so that people with AD who were in better shape had more brain tissue. There was no such relationship in people without dementia, and there was no correlation between brain volume and cognitive measures after adjustment for age.

From the data, the authors conclude, “Increased cardiorespiratory fitness is associated with reduced brain atrophy in Alzheimer disease.” That does not mean keeping fit staves off brain loss, they caution. The association could just as likely result from a situation where loss of fitness accompanies AD, or where some underlying process affects both fitness and AD progression. Studies in mice support the appealing idea that fitness can moderate the attack of AD on the brain—exercise reduces amyloid pathology in mouse models of AD (see ARF related news story and Adlard et al., 2005) and stimulates learning and neurogenesis in normal adult mice (see ARF related news story). However, moving from association to causation in humans will require further studies.—Pat McCaffrey.

References:
Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, Fogarty J, Bartha R, and the Alzheimer's Disease Neuroimaging Initiative. Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging database. Brain. 2008 July 11, advance access. Abstract

Burns JM, Cronk BB, Anderson HS, Donnelly JE, Thomas GP, Harsha A, Brooks WM, Swerdlow RH. Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology. 2008 Jul 15;71(3):210-216. Abstract

 
Comments on News and Primary Papers
  Primary Papers: Cardiorespiratory fitness and brain atrophy in early Alzheimer disease.

Comment by:  Patricia Heyn
Submitted 29 July 2008  |  Permalink Posted 29 July 2008

This study by Burns and colleagues adds optimistically to the growing body of evidence supporting that aerobic-based physical activities, which improve cardiorespiratory fitness, are beneficial for cognitive function. There are certainly numerous possible reasons why exercise training improves cognitive function.

The results showed that participants who were more physically fit had less brain shrinkage than less-fit participants. However, they did not do significantly better on tests of mental performance. Although the authors were surprised by the small effect of exercise on cognitive performance, this should not be taken as unusual. There are several reasons why there was no significant effect between fitness and cognitive performance. For example: 1) the tests used were not sensitive enough to capture the subtle changes of exercise on cognitive function; 2) the study results were based on participants who were evaluated only once rather than repeatedly over time; and 3) the study sample was too small to show a statistically significant effect.

Even though the study...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad